Ogrodnik et al. demonstrated that elimination of hepatic senescent cells via targeting the p16INK4A senescence regulator may be a novel therapeutic strategy to reduce hepatic steatosis [96]. This evidence concerns the gene CDKN2A and fatty liver disease.